The exact PDUFA date isn’t disclosed, but it should be during Oct/Nov 2015. GT4 represents 6% of the US HCV population, but its economic relevance for ENTA is greater than the 6% figure would suggest because ENTA’s royalty rate is based on 45% of the 2-DAA regimen’s sales (rather than 30% for the 3-DAA V-Pak).